JP2003532426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003532426A5 JP2003532426A5 JP2001582562A JP2001582562A JP2003532426A5 JP 2003532426 A5 JP2003532426 A5 JP 2003532426A5 JP 2001582562 A JP2001582562 A JP 2001582562A JP 2001582562 A JP2001582562 A JP 2001582562A JP 2003532426 A5 JP2003532426 A5 JP 2003532426A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- ltr
- sequences
- vector
- heterologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 description 82
- 230000001177 retroviral effect Effects 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 30
- 108091026890 Coding region Proteins 0.000 description 20
- 230000008488 polyadenylation Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 239000002245 particle Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000005030 transcription termination Effects 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000037430 deletion Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000013715 transcription antitermination Effects 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102100031609 Complement C2 Human genes 0.000 description 1
- 108090000955 Complement C2 Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000700735 Ground squirrel hepatitis virus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100026519 Lamin-B2 Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010052219 lamin B2 Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20388400P | 2000-05-12 | 2000-05-12 | |
| US60/203,884 | 2000-05-12 | ||
| PCT/IB2001/000826 WO2001085974A2 (en) | 2000-05-12 | 2001-05-14 | Retroviral vectors comprising an enhanced 3' transcription termination structure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003532426A JP2003532426A (ja) | 2003-11-05 |
| JP2003532426A5 true JP2003532426A5 (enExample) | 2008-07-03 |
| JP4708661B2 JP4708661B2 (ja) | 2011-06-22 |
Family
ID=22755701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001582562A Expired - Fee Related JP4708661B2 (ja) | 2000-05-12 | 2001-05-14 | 増強された３’転写終結構造を含む、レトロウイルスベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6620595B2 (enExample) |
| EP (1) | EP1283895A2 (enExample) |
| JP (1) | JP4708661B2 (enExample) |
| AU (1) | AU2001258668A1 (enExample) |
| CA (1) | CA2408786C (enExample) |
| IL (2) | IL152527A0 (enExample) |
| NZ (1) | NZ522264A (enExample) |
| WO (1) | WO2001085974A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1412493T3 (da) | 2001-08-02 | 2012-01-09 | Inst Clayton De La Rech | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer |
| PL1794308T3 (pl) * | 2004-09-29 | 2014-04-30 | Pioneer Hi Bred Int | Zdarzenie DAS-59122-7 kukurydzy oraz sposoby jego wykrycia |
| EP2598636A4 (en) * | 2010-07-26 | 2014-03-05 | Adv Biolog Inc | VECTORS AND METHODS FOR EXPRESSION OF RECOMBINANT PROTEINS |
| CN102443604B (zh) * | 2011-11-25 | 2014-12-31 | 上海市儿童医院 | 一种安全性慢病毒载体及其应用 |
| CN102533863A (zh) * | 2011-11-25 | 2012-07-04 | 上海市儿童医院 | 一种低通读率慢病毒载体及方法 |
| EA201591229A1 (ru) * | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
-
2001
- 2001-05-14 NZ NZ522264A patent/NZ522264A/en not_active IP Right Cessation
- 2001-05-14 EP EP01931987A patent/EP1283895A2/en not_active Withdrawn
- 2001-05-14 IL IL15252701A patent/IL152527A0/xx unknown
- 2001-05-14 WO PCT/IB2001/000826 patent/WO2001085974A2/en not_active Ceased
- 2001-05-14 JP JP2001582562A patent/JP4708661B2/ja not_active Expired - Fee Related
- 2001-05-14 AU AU2001258668A patent/AU2001258668A1/en not_active Abandoned
- 2001-05-14 US US09/855,159 patent/US6620595B2/en not_active Expired - Lifetime
- 2001-05-14 CA CA2408786A patent/CA2408786C/en not_active Expired - Fee Related
-
2002
- 2002-10-28 IL IL152527A patent/IL152527A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Naldini et al. | Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. | |
| Miyoshi et al. | Development of a self-inactivating lentivirus vector | |
| US7056699B2 (en) | Lentiviral LTR-deleted vector | |
| ES2607484T3 (es) | Utilización de secuencias de lentivirus de estructura triple para la importación nuclear de secuencias nucleotídicas | |
| US6541219B1 (en) | Therapeutic Gene | |
| ES2245042T3 (es) | Vectores de lentivirus de no primates y sistemas de empaquetamiento. | |
| ES2411981T3 (es) | Vector lentivírico | |
| JP3886531B2 (ja) | レトロウイルスベクター | |
| KR20000049250A (ko) | 렌티바이러스 벡터 | |
| KR20040054699A (ko) | 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물 | |
| US6096534A (en) | Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells | |
| Metharom et al. | Novel bovine lentiviral vectors based on Jembrana disease virus | |
| Condiotti et al. | Prolonged liver-specific transgene expression by a non-primate lentiviral vector | |
| Loewen et al. | Lentiviral vectors | |
| JP2003532426A5 (enExample) | ||
| US20060019393A1 (en) | Minimal lentiviral vector system | |
| JP4708661B2 (ja) | 増強された３’転写終結構造を含む、レトロウイルスベクター | |
| US7608449B2 (en) | Methods and compositions related to high-titer pseudotyped retroviruses | |
| AU734968B2 (en) | Vectors for inhibiting HIV and tumor growth | |
| JP2001502904A (ja) | レトロウイルスベクター | |
| DE69829174T2 (de) | Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein) | |
| JP2016067306A (ja) | ヒト免疫不全ウイルスの感染防御方法 | |
| JP2023502593A (ja) | Ｘ連鎖慢性肉芽腫症を治療するための、造血幹細胞中のレンチウイルスベクター | |
| Croyle et al. | 892. Purification of Recombinant Lentiviral V 892. Purification of Recombinant Lentiviral Vector by Anion Exchange Chromatography | |
| Element | 827. Integration and Biodistribution Studies of Retroviral Vector in Mouse Gonad Tissues |